Combined hepatitis A and B vaccine: providing a bright future for preventing hepatitis

Bibliography

• Center for disease control and prevention. Disease burden from viral hepatitis A, B, and C in the United States. Available from: http://www.cdc.gov/hepatitis/Statistics.htm. [Last accessed 6 July 2009]
   Google Scholar
• Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus super-infection in patients with chronic C. N Engl J Med 1998;338:286-90
   PubMed Web of Science ®Google Scholar
• Keefe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol 1995;90:201-5
   PubMed Web of Science ®Google Scholar
• Feray C, Gigou M. et al. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. Gastroenterology 1993;104:549-55
   PubMed Web of Science ®Google Scholar
• Modlin JF, Snider DE, Clover RD, et al. Centers for disease control and prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999;48(RR-12):1-37
   Google Scholar
• Katz SL, Montage JL, Hardegree C, et al. Centers for disease control and prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1991;40(RR-13):1-19
   Google Scholar
• Mahoney FJ, Kane M. Hepatitis B vaccine. In: Plotkin SA, Orenstein WA, editors, Vaccines, 3rd edition. Philadelphia: WB Saunders, 1999. p. 650-71
   Google Scholar
• Twinri® US prescribing information. Philadelphia (PA): GlaxoSmithKline Biologicals, April 2007
   Google Scholar
• Ambrosch F, Wiedermann G, Andre FE, et al. Clinical and immunological investigation of a new combined hepatitis A and hepatitis B vaccine. J Med Virol 1994;44:452-6
   PubMed Web of Science ®Google Scholar
• Thoelen S, Van Damme P, Leentvaar-Kuypers A, et al. The first combined vaccine against hepatitis A and B: an overview. Vaccine 1999;17:1657-62
   PubMed Web of Science ®Google Scholar
• Joines R, Blatter M, Abraham B, et al. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults. Vaccine 2001;19:4710-9
   PubMed Web of Science ®Google Scholar
• Knoll A, Hottentrager B, Kainz J, et al. Immunogenicity of a combined hepatitis A and B vaccine in healthy young adults. Vaccine 2000;18:2029-32
   PubMed Web of Science ®Google Scholar
• Van Herck K, Leroux-Roels G, Van Damme P, et al. Ten-year antibody persistence induced by hepatitis A and B vaccine (Twinrix) in adults. Travel Med Infect Dis 2007;5(3):171-5
   PubMedGoogle Scholar
• Diaz-Mitoma F, Law B, Subramanya A, Hoet B. Long term antibody persistence induced by a combined hepatitis A and B vaccine in children and adolescents. Vaccine 2008;26:1759-63
   PubMed Web of Science ®Google Scholar
• Van der Wielen M, Van Damme P, Chlibek R, et al. Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors. Vaccine 2006;24:5509-15
   PubMed Web of Science ®Google Scholar
• Cardell K, Akerlind B, Sallberg M, Fryden A. Excellent response rate to a double dose of combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. J Infect Dis 2008;198(3):299-304
   PubMed Web of Science ®Google Scholar
• Villano SA, Nelson KE, Vlahov D, et al. Hepatitis A among homosexual men and injection drug users: more evidence for vaccination. Clin Infect Dis 1997;25:726-8
   PubMed Web of Science ®Google Scholar
• Lugoboni F, Quaglio G, Pajusco B, et al. Immunogenicity, reactogenicity and adherence to a combined hepatitis A and B vaccine in illict drug users. Addiction 2004;99:1560-4
   PubMed Web of Science ®Google Scholar
• Rogers N, Lubman DI. An accelerated hepatitis B vaccination schedule for young drug users. Aust NZ J Public Health 2002;5:324-6
   Google Scholar
• Jacobs JR, Gibson GA, Meyerhoff AS. Cost-effectiveness of hepatitis A and B vaccine for healthcare and public safety workers in the western United States. Infect Control Hosp Epidemiol 2004;25:563-9
   PubMed Web of Science ®Google Scholar
• Keystone JS. Travel-related hepatitis B: risk factors and prevention using an accelerated vaccination schedule. Am J Med 2005;118:63-8S
   Web of Science ®Google Scholar
• Nothdurft HD, Dietrich M, Zuckerman JN, et al. A new accelerated vaccination schedule for rapid protection against hepatitis A and B. Vaccine 2002;20:1157-62
   PubMed Web of Science ®Google Scholar
• Nothdurft HD, Zuckerman J, Stoffel M, et al. Accelerated vaccination schedules provide protection against hepatitis A and B in last minute travelers. J Travel Med 2004;11:260-1
   PubMed Web of Science ®Google Scholar
• Ramonet M, Reverbel da Silveira T, Lisker-Melman M, et al. A two-dose combined vaccine against hepatitis A and B in healthy children and adolescents compared to the corresponding monovalent vaccines. Arch Med Res 2002;33:67-73
   PubMed Web of Science ®Google Scholar
• Kaur S, Handa S. Erythema multiforme following vaccination in an infant. Indian J Dermatol Venereol Leprol 2008;74:251-3
   PubMed Web of Science ®Google Scholar
• Csepregi A, Treiber G, Rocken C, Malfertheiner P. Acute exacerbation of autoimmune hepatitis induced by Twinrix. World J Gastroenterol 2005;11:4114-6
   PubMed Web of Science ®Google Scholar
• Van Damme P, Leroux-Roels G, Law B, et al. Long-term persistence of antibodies induced by vaccination and safety follow up, with the first combined vaccine against hepatitis A and B in children and adults. J Med Virol 2001;65:6-13
   PubMed Web of Science ®Google Scholar
• Sjogren MH. Prevention of hepatitis in nonresponders to initial hepatitis B virus vaccination. Am J Med 2005;118(Suppl 10A):34S-39S
   PubMed Web of Science ®Google Scholar